Every round on record, with the sources behind each and the investors on them.
A biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis
hibercell.comLinkedInNew YorkBiotechFounded 2019
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60.8M | ~ 2019-02-07 | Arch Venture Partners | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source | ||||
HiberCell develops cancer therapeutics that target adaptive stress pathways in cancer cells to help patients live longer, cancer-free lives by reducing treatment resistance, relapse, and metastasis.
Checked against 8 sources today
Also named as backers in company research: Hillhouse Capital, Hercules Capital